Literature DB >> 34050694

Epigenetic regulation in medulloblastoma pathogenesis revealed by genetically engineered mouse models.

Ryo Shiraishi1,2, Daisuke Kawauchi1.   

Abstract

Medulloblastoma is the most common malignant cerebellar tumor in children. Recent technological advances in multi-layered omics data analysis have revealed four molecular subgroups of medulloblastoma (Wingless/int, Sonic hedgehog, Group3 and Group4). (Epi)genomic and transcriptomic profiling on human primary medulloblastomas show distinct oncogenic drivers and cellular origin(s) across the subgroups. Despite tremendous efforts to identify the molecular signals driving tumorigenesis, few of the identified targets are druggable; therefore, further understanding of the etiology of tumors is required to establish effective molecular targeted therapies. Chromatin regulators are frequently mutated in medulloblastoma, prompting us to investigate epigenetic alterations and the accompanying activation of oncogenic signaling during tumorigenesis. For this purpose, we use germline and non-germline genetically engineered mice to model human medulloblastoma and to generate useful, molecularly-targeted, preclinical studies. This review discusses the biological implications of chromatin regulator mutations during medulloblastoma pathogenesis, based on recent in vivo animal studies. This article is protected by copyright. All rights reserved.

Entities:  

Keywords:  cerebellar development; chromatin regulator; medulloblastoma; mouse model; pediatric brain tumor

Year:  2021        PMID: 34050694     DOI: 10.1111/cas.14990

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  2 in total

1.  Novel Quinoline Compounds as EZH2 Inhibitors for Treating Cancer.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2022-04-13       Impact factor: 4.632

Review 2.  The current landscape of immunotherapy for pediatric brain tumors.

Authors:  Eugene I Hwang; Elias J Sayour; Catherine T Flores; Gerald Grant; Robert Wechsler-Reya; Lan B Hoang-Minh; Mark W Kieran; Joanne Salcido; Robert M Prins; John W Figg; Michael Platten; Kate M Candelario; Paul G Hale; Jason E Blatt; Lance S Governale; Hideho Okada; Duane A Mitchell; Ian F Pollack
Journal:  Nat Cancer       Date:  2022-01-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.